Advertisement
The Journal of Heart and Lung Transplantation
International Society for Heart and Lung Transplantation.

Plasma protein biosignatures for detection of cardiac allograft vasculopathy

      Background

      Coronary angiography remains the most widely used tool for routine screening and diagnosis of cardiac allograft vasculopathy (CAV), a major pathologic process that develops in 50% of cardiac transplant recipients beyond the first year after transplant. Given the invasiveness, expense, discomfort, and risk of complications associated with angiography, a minimally invasive alternative that is sensitive and specific would be highly desirable for monitoring CAV in patients.

      Methods

      Plasma proteomic analysis using isobaric tags for relative and absolute quantitation–matrix-assisted laser desorption ionization double time-of-flight mass spectrometry was carried out on samples from 40 cardiac transplant patients (10 CAV, 9 non-significant CAV, 21 possible CAV). Presence of CAV was defined as left anterior descending artery diameter stenosis ≥ 40% by digital angiography and quantitatively measured by blinded expert appraisal. Moderated t-test robust-linear models for microarray data were used to identify biomarkers that are significantly differentially expressed between patient samples with CAV and with non-significant CAV. A proteomic panel for diagnosis of CAV was generated using the Elastic Net classification method.

      Results

      We identified an 18-plasma protein biomarker classifier panel that was able to classify and differentiate patients with angiographically significant CAV from those without significant CAV, with an 80% sensitivity and 89% specificity, while providing insight into the possible underlying immune and non-alloimmune contributory mechanisms of CAV.

      Conclusion

      Our results support of the potential utility of proteomic biomarker panels as a minimally invasive means to identify patients with significant, angiographically detectable coronary artery stenosis in the cardiac allograft, in the context of post-cardiac transplantation monitoring and screening for CAV. The potential biologic significance of the biomarkers identified may also help improve our understanding of CAV pathophysiology.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The Journal of Heart and Lung Transplantation
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Christie J.D.
        • Edwards L.B.
        • Kucheryavaya A.Y.
        • et al.
        The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult lung and heart-lung transplant report—2010.
        J Heart Lung Transplant. 2010; 29: 1104-1118
        • Ramzy D.
        • Rao V.
        • Brahm J.
        • Miriuka S.
        • Delgado D.
        • Ross H.J.
        Cardiac allograft vasculopathy: a review.
        Can J Surg. 2005; 48: 319-327
        • Schmauss D.
        • Weis M.
        Cardiac allograft vasculopathy: recent developments.
        Circulation. 2008; 117: 2131-2141
        • Kass M.
        • Allan R.
        • Haddad H.
        Diagnosis of graft coronary artery disease.
        Curr Opin Cardiol. 2007; 22: 139-145
        • Yamani M.H.
        • Taylor D.O.
        • Rodriguez E.R.
        • et al.
        Transplant vasculopathy is associated with increased AlloMap gene expression score.
        J Heart Lung Transplant. 2007; 26: 403-406
        • Freue G.V.
        • Sasaki M.
        • Meredith A.
        • et al.
        Proteomic signatures in plasma during early acute renal allograft rejection.
        Mol Cell Proteomics. 2010; 9: 1954-1967
        • Deng M.C.
        • Eisen H.J.
        • Mehra M.R.
        • et al.
        Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling.
        Am J Transplant. 2006; 6: 150-160
        • Lin D.
        • Hollander Z.
        • Ng R.T.
        • et al.
        Whole blood genomic biomarkers of acute cardiac allograft rejection.
        J Heart Lung Transplant. 2009; 28: 927-935
      1. Protocol for long-term surveillance of cardiac allograft vasculopathy. 2007. http://www.heartcentre.ca/CADsurveillance2007.pdf.pdf. Accessed May 1, 2013.

        • Mancini G.B.
        • Yeoh E.
        • Kamimura C.
        • Abbott D.
        A comparison of quantitative coronary angiography systems using a unique set of in vivo coronary stenosis images.
        Can J Cardiol. 2001; 17: 785-791
        • Troyanskaya O.
        • Cantor M.
        • Sherlock G.
        • et al.
        Missing value estimation methods for DNA microarrays.
        Bioinformatics. 2001; 17: 520-525
        • Kim K.Y.
        • Kim B.J.
        • Yi G.S.
        Reuse of imputed data in microarray analysis increases imputation efficiency.
        BMC Bioinformatics. 2004; 5: 160
        • Zou H.
        • Hastie T.
        Regularization and variable selection via the elastic net.
        J R Statist Soc. 2005; B 67: 301-320
        • Sing T.
        • Sander O.
        • Beerenwinkel N.
        • Lengauer T.
        ROCR: visualizing classifier performance in R.
        Bioinformatics. 2005; 21: 3940-3941
      2. Team RDC, editor: R: a language environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2008

        • Mehra M.R.
        • Crespo-Leiro M.G.
        • Dipchand A.
        • et al.
        International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy—2010.
        J Heart Lung Transplant. 2010; 29: 717-727
        • Mehra M.R.
        • Uber P.A.
        • Potluri S.
        • Ventura H.O.
        • Scott R.L.
        • Park M.H.
        Usefulness of an elevated B-type natriuretic peptide to predict allograft failure, cardiac allograft vasculopathy, and survival after heart transplantation.
        Am J Cardiol. 2004; 94: 454-458
        • Keogh A.M.
        • Valantine H.A.
        • Hunt S.A.
        • et al.
        Impact of proximal or midvessel discrete coronary artery stenoses on survival after heart transplantation.
        J Heart Lung Transplant. 1992; 11: 892-901
        • Wehner J.
        • Morrell C.N.
        • Reynolds T.
        • Rodriguez E.R.
        • Baldwin 3rd, W.M.
        Antibody and complement in transplant vasculopathy.
        Circ Res. 2007; 100: 191-203
        • Moller-Kristensen M.
        • Thiel S.
        • Sjoholm A.
        • Matsushita M.
        • Jensenius J.C.
        Cooperation between MASP-1 and MASP-2 in the generation of C3 convertase through the MBL pathway.
        Int Immunol. 2007; 19: 141-149
        • Vorup-Jensen T.
        • Jensenius J.C.
        • Thiel S.
        MASP-2, the C3 convertase generating protease of the MBLectin complement activating pathway.
        Immunobiology. 1998; 199: 348-357
        • Honore C.
        • Hummelshoj T.
        • Hansen B.E.
        • Madsen H.O.
        • Eggleton P.
        • Garred P.
        The innate immune component ficolin 3 (Hakata antigen) mediates the clearance of late apoptotic cells.
        Arthritis Rheum. 2007; 56: 1598-1607
        • Guo L.
        • Deshmukh H.
        • Lu R.
        • et al.
        Replication of the BANK1 genetic association with systemic lupus erythematosus in a European-derived population.
        Genes Immun. 2009; 10: 531-538
        • Kaufman C.L.
        • Ouseph R.
        • Blair B.
        • et al.
        Graft vasculopathy in clinical hand transplantation.
        Am J Transplant. 2012; 12: 1004-1016
        • Petersen C.M.
        Alpha 2-macroglobulin and pregnancy zone protein. Serum levels, alpha 2-macroglobulin receptors, cellular synthesis and aspects of function in relation to immunology.
        Dan Med Bull. 1993; 40: 409-446
        • Skornicka E.L.
        • Kiyatkina N.
        • Weber M.C.
        • Tykocinski M.L.
        • Koo P.H.
        Pregnancy zone protein is a carrier and modulator of placental protein-14 in T-cell growth and cytokine production.
        Cell Immunol. 2004; 232: 144-156
        • Svendsen P.
        • Stigbrand T.
        • Teisner B.
        • et al.
        Immunosuppressive effect of human pregnancy zone protein on H-2 incompatible mouse heart allografts.
        Acta Pathol Microbiol Scand C. 1978; 86c: 199-201
        • Afandi B.
        • Vera R.
        • Schussler G.C.
        • Yap M.G.
        Concordant decreases of thyroxine and thyroxine binding protein concentrations during sepsis.
        Metabolism. 2000; 49: 753-754
        • Gabay C.
        • Kushner I.
        Acute-phase proteins and other systemic responses to inflammation.
        N Engl J Med. 1999; 340: 448-454
        • Roth-Isigkeit A.K.
        • Dibbelt L.
        • Schmucker P.
        Blood levels of corticosteroid-binding globulin, total cortisol and unbound cortisol in patients undergoing coronary artery bypass grafting surgery with cardiopulmonary bypass.
        Steroids. 2000; 65: 513-520
        • Massoud O.
        • Heimbach J.
        • Viker K.
        • et al.
        Noninvasive diagnosis of acute cellular rejection in liver transplant recipients: a proteomic signature validated by enzyme-linked immunosorbent assay.
        Liver Transpl. 2011; 17: 723-732
        • Rahmani M.
        • Cruz R.P.
        • Granville D.J.
        • McManus B.M.
        Allograft vasculopathy versus atherosclerosis.
        Circ Res. 2006; 99: 801-815
        • Anderson L.
        Candidate-based proteomics in the search for biomarkers of cardiovascular disease.
        J Physiol. 2005; 563: 23-60
        • Kwiatkowski D.J.
        Functions of gelsolin: motility, signaling, apoptosis, cancer.
        Curr Opin Cell Biol. 1999; 11: 103-108
        • Nishio R.
        • Matsumori A.
        Gelsolin and cardiac myocyte apoptosis: a new target in the treatment of postinfarction remodeling.
        Circ Res. 2009; 104: 829-831
        • Silacci P.
        • Mazzolai L.
        • Gauci C.
        • Stergiopulos N.
        • Yin H.L.
        • Hayoz D.
        Gelsolin superfamily proteins: key regulators of cellular functions.
        Cell Mol Life Sci. 2004; 61: 2614-2623
        • DiNubile M.J.
        Plasma gelsolin as a biomarker of inflammation.
        Arthritis Res Ther. 2008; 10: 124
        • Schober A.
        • Hristov M.
        • Kofler S.
        • et al.
        CD34+CD140b+ cells and circulating CXCL12 correlate with the angiographically assessed severity of cardiac allograft vasculopathy.
        Eur Heart J. 2011; 32: 476-484
        • Simper D.
        • Mayr U.
        • Urbich C.
        • et al.
        Comparative proteomics profiling reveals role of smooth muscle progenitors in extracellular matrix production.
        Arterioscler Thromb Vasc Biol. 2010; 30: 1325-1332
        • Rafflenbeul W.
        • Urthaler F.
        • Lichtlen P.
        • James T.N.
        Quantitative difference in “critical” stenosis between right and left coronary artery in man.
        Circulation. 1980; 62: 1188-1196
        • Qian Z.
        • Anderson H.
        • Marvasty I.
        • et al.
        Lesion- and vessel-specific coronary artery calcium scores are superior to whole-heart Agatston and volume scores in the diagnosis of obstructive coronary artery disease.
        J Cardiovasc Comput Tomogr. 2010; 4: 391-399